Loading...
•
Dec 31, 2019
Cassava Sciences Q4 2019 Earnings Report
Reported financial results for the year ended December 31, 2019, and provided corporate milestones for 2020.
Key Takeaways
Cassava Sciences reported a net loss of $4.6 million for the full year 2019, with cash and cash equivalents totaling $23.1 million as of December 31, 2019. The company anticipates net cash use of approximately $5 million for the full year 2020 and is focused on advancing its Alzheimer's disease product candidates.
Net loss for full-year 2019 was $4.6 million, or $0.27 per share.
Cash and cash equivalents were $23.1 million as of December 31, 2019.
Net cash used in operations in full-year 2019 was $2.5 million.
The company received $3.6 million from warrant exercises, increasing cash balance to over $26 million by January 31, 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...